Search

477 Result(s)
Sort by

Netherton Syndrome

Netherton Syndrome

Information on Netherton Syndrome, a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
Really Digital, Mr Hach!

Really Digital, Mr Hach!

The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
Early careers

Early careers

At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Our Expectations

Our Expectations

We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
Do we keep our promise?

Do we keep our promise?

Find out from a father-daughter duo how we live up to our new People Promise.
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Improving Access to Healthcare

Improving Access to Healthcare

According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
CAROLINA-CARMELINA-Asia-analysis

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Boehringer acquires T3 Pharma

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Anna Race

Anna Race

Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.